1. Agthe AG, Dörffel W, Neuendank A, Hartmann R, Brühmüller S, Klumper E, Pieters R, Veerman AJP, Henze G (1997) Tailored therapy for relapsed or refractory childhood acute lymphoblastic leukemia. In: Pieters R, Kaspers GJL, Veerman AJP (eds) Drug resistance in leukemia and lymphoma II. Harwood Academic, Amsterdam, pp 51–57
2. Asselin BL, Kreissman S, Coppola DJ, Bernal SD, Leavitt PR, Gelber RD, Sallan SE, Cohen HJ (1999) Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 21:6–12
3. Bresters D, Broekhuizen R, Jimeno J, Faircloth GT, Kaspers GJL (2002a) Different cytotoxic activity in vitro of aplidine in pediatric leukemic and normal bone marrow and blood samples. Proc Am Assoc Cancer Res 43:924 (#4579)
4. Bresters D, Broekhuizen R, Jimeno J, Faircloth GT, Kaspers GJL (2002b) Lack of in vitro cross-resistance between Aplidine and other drugs in childhood leukemia and normal bone marrow and blood samples. Proc Am Assoc Cancer Res 43:925 (#4583)
5. Cortazar P, Johnson BE (1999) Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol 17:1625–1631